AI-generated analysis. Always verify with the original filing.
Maze Therapeutics reported fourth quarter and full year 2025 financial results with $360.0 million in cash supporting operations into 2028, announced positive Phase 2 HORIZON topline data for MZE829 showing 35.6% mean uACR reduction in broad AMKD patients, and appointed Neil Kumar as a Class I director effective March 27, 2026. These disclosures provide clinical proof-of-concept, financial visibility, and strengthened board expertise.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as am
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 24,
of this Current Report on Form 8-K, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to
Financial Statements and Exhibits. Exhibit Number Description 99.1 99.2 Press Release announcing financial results, dated March 25, 2026. Press Release announci
| Metric | Value | Basis |
|---|---|---|
| License Revenue | $0.00 | GAAP |
| Research and Development Expenses | $27.57 | GAAP |
| General and Administrative Expenses | $10.49 | GAAP |
| Net Loss | $34.57 | GAAP |
| Net Loss per Share Basic | $-0.65 | GAAP |
Neil Kumar
Effective: 2026-03-27
N/A